A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 10, 2011, Pages 931-935

  Halfon, Philippe ^a   Bourliere, Marc ^b   Ouzan, Denis ^e   Maor, Yaakov ⁱ   Renou, Christophe ^f   Wartelle, Claire ^g   Pénaranda, Guillaume ^a   Tran, Albert ^h   Botta, Danielle ^c   Oules, Valérie ^b   Castellani, Paul ^b   Portal, Isabelle ^c   Argiro, Laurent ^d   Dessein, Alain ^d  

^a Hospital Ambroise Pare   (France)

^b HÔPITAL SAINT JOSEPH   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

^d Aix Marseille university   (France)

^e INSTITUT ARNAULT TZANCK   (France)

^f Hopital d'Hyeres   (France)

^g CH Aix   (France)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁱ SHEBA MEDICAL CENTER   (Israel)

Author keywords

IL 28; single polynucleotide polymorphisms; sustained virologic response

Indexed keywords

ADULT; ARTICLE; DNA EXTRACTION; FEMALE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENE FREQUENCY; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80052660473     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328349d0ef     Document Type: Article

References (20)

1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
3. Hadziyannis SJ, Sette H Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
4. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338-1345.
5. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
6. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
7. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138:2307-2314.
8. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
9. Tillmann HL, Thompson A, Patel K, Wiese M,Tenckhoff H, Nischalke H, et al. IL28B polymorphism is associated with jaundice during acute HCV infection and is a strong predictor for spontaneous clearance in the prospective german anti-D cohort. J Hepatol 2010; 52:S56.
10. Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52:1216-1224.
11. Balagopal A, Thomas DL, Thio CL. IL28B and the Control of Hepatitis C Virus Infection. Gastroenterology 2010; 139:1865-1876.
12. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139:821-827, 827 e821.
13. Gervais A, Martinot M, Boyer N, Auperin A, Le Breton W, Degott C, et al. Quantitation of hepatic hepatitis C virus RNA in patients with chronic hepatitis C. Relationship with severity of disease, viral genotype and response to treatment. J hepatol 2001; 35:399-405. (Pubitemid 32844195)
14. Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol 2011; 106:38-45.
15. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
16. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139:e118.
17. Halfon P, Bourlière M, Ouzan D, Renou C, Wartelle C, Pénaranda G, et al. IL-28 gene variation predicts who will respond to interferon-based treatment of chronic hepatitis C in a french cohort. J Hepatol 2010; 52:S451.
18. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, Romero-Gomez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52:33-37.
19. Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010; 51:788-795.
20. Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. Aids 2010; 24:F23-F29.